Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Pharmaceuticals has extended its agreement with BARDA to supply additional doses of Inmazeb, its FDA-approved Ebola treatment, through 2031 for approximately $270 million. The company is also advancing maftivimab, a component of Inmazeb, as a potential monotherapy treatment for Bundibugyo virus disease in the current outbreak in the Democratic Republic of the Congo.

10/26/2026, 7:00 AM • GlobeNewswire

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Regeneron announced longer-term data (44-month follow-up) from the Phase 3 C-POST trial showing Libtayo (cemiplimab) as adjuvant treatment for high-risk cutaneous squamous cell carcinoma demonstrated a 37% reduction in risk of death compared to placebo, with sustained disease-free survival benefits. The drug was approved by the FDA in October 2025 and European Commission in November 2025 as the first immunotherapy for this indication.

10/25/2026, 5:15 AM • GlobeNewswire

Facing Investing Fears

A Motley Fool podcast discusses how historical S-1 risk factors from Amazon, Alphabet, and Meta didn't materialize into existential threats, offering perspective on Anthropic's alarming AI risks. The hosts identify stocks hitting new lows amid market fear—including Brookfield Corporation, Shopify, and Realty Income—while explaining how rising bond yields create both challenges for growth stocks and opportunities for cash-rich businesses and financial institutions.

10/23/2026, 10:29 AM • The Motley Fool

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

Regeneron Pharmaceuticals is emerging as a competitive player in the rapidly growing weight loss market with two differentiated candidates: olatorepatide, which shows better gastrointestinal tolerability than competitors with 19% mean weight loss, and trevogrumab, designed to preserve lean muscle mass alongside anti-obesity drugs. Beyond weight loss, Regeneron's strong pipeline including Dupixent and newer Eylea HD formulation positions it for medium-term growth.

10/19/2026, 10:24 AM • The Motley Fool

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.

10/17/2026, 3:24 PM • The Motley Fool

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved cancer indications. The new regimen allows for extended dosing of 700 mg every six weeks after an initial 12-week treatment with 350 mg every three weeks, and optional reduction of infusion time to 15-30 minutes. The European Commission is expected to make a final decision in the coming months.

10/16/2026, 7:00 AM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.

10/06/2026, 5:36 PM • GlobeNewswire

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Regeneron announced presentations of new clinical research at ESMO Congress 2026, highlighting late-breaking Phase 3 data for Libtayo (cemiplimab) in cutaneous squamous cell carcinoma, Phase 2 neoadjuvant treatment data, and new research on Factor XI antibodies for cancer-associated thrombosis. The company is presenting 10 abstracts covering trials in CSCC, NSCLC, ovarian cancer, melanoma, and cancer-associated thrombosis.

10/06/2026, 7:00 AM • GlobeNewswire

Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »

Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.

10/06/2026, 1:30 AM • GlobeNewswire

Press Release : Availability of the aide-mémoire for Q3 2026 results

Sanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.

10/06/2026, 1:30 AM • GlobeNewswire

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

10/01/2026, 12:30 PM • The Motley Fool

Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities

The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.

09/30/2026, 4:59 AM • GlobeNewswire

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?

Regeneron Pharmaceuticals stock has underperformed this year, down around 1%, but the company demonstrated strong fundamentals in its last earnings report with 17% revenue growth and impressive drug sales. With a modest valuation (19x trailing earnings vs. S&P 500's 23x), a robust pipeline of 50 product candidates, and upcoming Q3 earnings on Oct. 30, analysts suggest the stock could be poised for a rally and represents a solid value buy for long-term investors.

09/28/2026, 1:05 PM • The Motley Fool

Is Regeneron Stock a Bargain Below $800?

Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.

09/22/2026, 3:15 PM • The Motley Fool

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

09/22/2026, 10:59 AM • GlobeNewswire